Insulin, Metformin , Oral Hypoglycemic agents pharmacology notes in details

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I have sufficient information from multiple authoritative textbooks (Katzung, Goldman-Cecil, Ganong, Lippincott) to compile comprehensive pharmacology notes. Let me now compose the detailed notes.

📚 Pharmacology Notes: Insulin, Metformin & Oral Hypoglycemic Agents

Sources: Katzung's Basic & Clinical Pharmacology 16e, Goldman-Cecil Medicine, Lippincott Illustrated Reviews Pharmacology, Ganong's Review of Medical Physiology 26e

🔵 PART 1: INSULIN

Structure & Biosynthesis

Insulin is a polypeptide hormone secreted by pancreatic β cells (islets of Langerhans). It consists of two chains:

A chain: 21 amino acids
B chain: 30 amino acids
Linked by two disulfide bridges

Biosynthesis sequence: Preproinsulin → Proinsulin → Insulin + C-peptide (equimolar, clinically used to assess endogenous secretion)

Mechanism of Insulin Secretion

Glucose enters the β cell via GLUT2 transporters → undergoes glycolysis → raises ATP/ADP ratio → closes ATP-sensitive K⁺ channels (K_ATP) → membrane depolarization → opens voltage-gated Ca²⁺ channels → Ca²⁺ influx → exocytosis of insulin granules

Potentiators of secretion include:

Amino acids (arginine, leucine), β-keto acids
GLP-1, GIP (incretins)
Acetylcholine (M3 receptors), β₂-adrenergic stimulation
Increased cAMP (glucagon, β-agonists, theophylline)

Inhibitors: α₂-adrenergic stimulation (catecholamines, net effect), somatostatin, galanin

Mechanism of Action of Insulin

Insulin binds the insulin receptor (tyrosine kinase receptor):

Receptor autophosphorylation → activates IRS-1 and IRS-2 (insulin receptor substrates)
Activates PI3K → PDK1 → Akt (PKB) pathway
Triggers translocation of GLUT-4 transporters to cell surface (muscle, adipose)
Promotes glycogen synthesis (inhibits glycogen phosphorylase, activates glycogen synthase)
Promotes protein synthesis, lipogenesis, and inhibits lipolysis

Physiological Effects

Tissue	Effect
Liver	↑ glycogen synthesis, ↑ lipogenesis, ↓ gluconeogenesis, ↓ glycogenolysis
Muscle	↑ glucose uptake (GLUT-4), ↑ glycogen & protein synthesis
Adipose	↑ glucose uptake (GLUT-4), ↑ lipogenesis, ↓ lipolysis (inhibits hormone-sensitive lipase)
All cells	↑ K⁺ uptake (drives K⁺ intracellularly — used in hyperkalemia treatment)

Insulin Preparations

Classified by onset, peak, and duration of action:

🔴 Rapid-Acting (Insulin Analogs)

Preparation	Onset	Peak	Duration
Insulin lispro	5–15 min	30–90 min	3–5 h
Insulin aspart	5–15 min	30–90 min	3–5 h
Insulin glulisine	5–15 min	30–90 min	3–5 h

MOA modification: In lispro, B28-B29 proline-lysine are inverted → reduces self-aggregation → faster absorption from SC site

🟡 Short-Acting (Regular Insulin)

Preparation	Onset	Peak	Duration
Regular insulin	30–60 min	2–4 h	5–8 h

Given 30 min before meals. Only insulin that can be given IV (used in DKA, hyperkalemia, surgical patients).

🟢 Intermediate-Acting

Preparation	Onset	Peak	Duration
NPH (isophane)	1–2 h	6–10 h	16–24 h

NPH = Neutral Protamine Hagedorn — protamine added to delay absorption. Cloudy suspension.

🔵 Long-Acting (Basal Analogs)

Preparation	Onset	Peak	Duration
Insulin glargine	1–2 h	Peakless	~24 h
Insulin detemir	1–2 h	Minimal	18–24 h
Insulin degludec	1–2 h	Peakless	>42 h

Glargine mechanism: Acidic pH (4.0) in vial → at neutral SC pH, forms microprecipitate → slow absorption → stable basal coverage. Cannot be mixed with other insulins.

🟣 Premixed Combinations

70/30: 70% NPH + 30% Regular
75/25: 75% neutral protamine lispro + 25% lispro

Clinical Uses of Insulin

Type 1 Diabetes Mellitus (absolute indication — absolute insulin deficiency)
Type 2 DM (when oral agents fail, or HbA1c very high)
Diabetic Ketoacidosis (DKA) — IV regular insulin
Hyperkalemia — drives K⁺ into cells (given with dextrose)
Gestational diabetes (preferred over most oral agents)
Critically ill patients (surgical ICU — tight glucose control)

Insulin Regimens

Basal-bolus: Basal (long-acting once daily) + Bolus (rapid-acting with each meal) — most physiological
Basal only: For T2DM inadequately controlled on oral agents
Split-mixed: NPH + Regular twice daily (older regimen)

Adverse Effects of Insulin

Adverse Effect	Details
Hypoglycemia	Most dangerous; risk ↑ with excess dose, missed meals, exercise, alcohol
Weight gain	Anabolic effect; lipogenesis
Lipodystrophy	Lipoatrophy (old animal insulins) or lipohypertrophy (repeated injection at same site)
Hypokalemia	K⁺ shift into cells
Edema	Na⁺ retention (acute insulin therapy)
Allergic reactions	Rare with human insulin
Somogyi effect	Rebound hyperglycemia after nocturnal hypoglycemia
Dawn phenomenon	Early morning hyperglycemia from GH surge (physiological)

🟠 PART 2: METFORMIN

Drug Class

Biguanide — the only clinically used biguanide (phenformin/buformin withdrawn due to severe lactic acidosis risk)

Mechanism of Action

Metformin's primary actions:

↓ Hepatic gluconeogenesis (main effect) — inhibits mitochondrial complex I → ↓ ATP/ADP ratio → activates AMPK → inhibits PEPCK, G6Pase transcription → ↓ gluconeogenesis
↑ Peripheral insulin sensitivity — enhances insulin-stimulated glucose uptake in muscle
↓ Intestinal glucose absorption (minor contribution)
↓ Hepatic glycogenolysis

AMPK activation by metformin mimics the state of cellular energy depletion and has pleiotropic metabolic benefits beyond glycemic control.

Pharmacokinetics

Parameter	Detail
Bioavailability	~50–60% (intestinal absorption)
Protein binding	Negligible
Metabolism	NOT hepatically metabolized — excreted unchanged
Elimination	Renal tubular secretion (via OCT2 transporter)
Half-life	~6 hours (plasma); ~17 hours (whole blood)

Clinical Effects

Reduces HbA1c by 1.0–1.5%
Does NOT cause hypoglycemia (no effect on insulin secretion)
Weight neutral or promotes modest weight loss
Reduces cardiovascular events and mortality in obese T2DM patients (UKPDS evidence)
Preferred first-line therapy for Type 2 DM — Lippincott, Goldman-Cecil

Dosing

Start low: 500 mg once or twice daily with meals
Titrate slowly to reduce GI side effects
Maximum dose: 2550 mg/day (limited by GI tolerance and renal function)
Extended-release formulation improves GI tolerability

Adverse Effects

Adverse Effect	Details
GI symptoms	Nausea, diarrhea, bloating, anorexia — most common; dose-related; improve with time
Lactic acidosis	Rare but potentially fatal; risk ↑ in renal failure, hepatic dysfunction, hypoxia, sepsis, alcoholism
Vitamin B₁₂ deficiency	Long-term use → ↓ ileal absorption of B₁₂ (competes with intrinsic factor-B₁₂ complex) → worsening neuropathy → periodic B₁₂ testing recommended
Metallic taste	Common, transient

Contraindications

Contraindication	Reason
eGFR < 30 mL/min	Drug accumulates → lactic acidosis risk
Iodinated contrast agents	Hold temporarily (48 h before and after) — risk of acute kidney injury with contrast → drug accumulation
Hepatic failure	Impaired lactate clearance
Acute illness with dehydration	Renal hypoperfusion
Heavy alcohol use	Potentiates lactic acidosis

🟢 PART 3: OTHER ORAL HYPOGLYCEMIC AGENTS

3.1 SULFONYLUREAS (First-generation & Second-generation)

Mechanism of Action

Sulfonylureas bind to the SUR1 subunit of K_ATP channels on β-cell membrane → block K⁺ efflux → membrane depolarization → Ca²⁺ influx → insulin secretion (glucose-independent)

Require functional β cells — ineffective in T1DM or after pancreatectomy
Act independent of plasma glucose levels → risk of hypoglycemia even in euglycemia

Drug List

1st Generation (older, more side effects):

Tolbutamide, Chlorpropamide, Tolazamide, Acetohexamide

2nd Generation (preferred — more potent, fewer interactions):

Glipizide — short-acting, preferred in elderly/renal disease
Glyburide (Glibenclamide) — active metabolites → higher hypoglycemia risk
Glimepiride — once daily, lowest hypoglycemia risk among SUs
Gliclazide — cardioprotective profile

Pharmacokinetics (2nd gen)

Good oral bioavailability
Hepatically metabolized (CYP2C9)
Glipizide: inactive metabolites; Glyburide: active metabolites (avoid in renal/elderly)
Highly protein-bound — drug interactions with NSAIDs, warfarin, sulfonamides (displace → ↑ effect)

Clinical Effects

Reduce HbA1c by 1.0–2.0%
↑ Weight (anabolic — insulin secretion)

Adverse Effects

Effect	Details
Hypoglycemia	Most important; prolonged with long-acting agents (glyburide)
Weight gain	Due to hyperinsulinemia
Hyponatremia (SIADH)	Chlorpropamide (1st gen) potentiates ADH
Disulfiram-like reaction	Chlorpropamide with alcohol
Hematological	Agranulocytosis, hemolytic anemia (rare)
Photosensitivity	Chlorpropamide

3.2 MEGLITINIDES (Non-Sulfonylurea Insulin Secretagogues)

Drugs

Repaglinide — also has PPAR-γ activity
Nateglinide — derivative of D-phenylalanine

Mechanism

Bind to different site on SUR1 of K_ATP channel (same ultimate effect as sulfonylureas) → ↑ insulin secretion

Key Features

Rapid-acting, short-duration — taken just before each meal (→ control postprandial glucose)
Useful when meal timing is irregular
Shorter hypoglycemia risk window than sulfonylureas
Repaglinide hepatically metabolized → usable in renal disease
Nateglinide: only effective in presence of glucose (glucose-dependent to some extent)

3.3 BIGUANIDES — Metformin (covered above)

3.4 THIAZOLIDINEDIONES (TZDs / Glitazones)

Drugs

Pioglitazone (currently used)
Rosiglitazone (restricted — CV concerns)
Troglitazone (withdrawn — hepatotoxicity)

Mechanism

Bind to and activate PPARγ (Peroxisome Proliferator-Activated Receptor-γ) — a nuclear transcription factor in adipocytes → regulates genes involved in glucose and lipid metabolism → ↑ insulin sensitivity in adipose tissue, muscle, and liver

↑ GLUT-4 expression
↑ Adiponectin (anti-inflammatory, insulin-sensitizing adipokine)
↓ Free fatty acids
↓ Hepatic gluconeogenesis

Clinical Effects

Reduce HbA1c by 0.5–1.4%
Do NOT cause hypoglycemia (no insulin secretion)
Pioglitazone: favorable lipid profile (↑ HDL, ↓ TG)

Adverse Effects

Effect	Details
Fluid retention / edema	↑ Na⁺ reabsorption → fluid retention
Weight gain	↑ Adipogenesis
Heart failure exacerbation	Contraindicated in NYHA Class III–IV HF
Bone fractures	↑ risk in women (peripheral bones)
Bladder cancer risk	Pioglitazone (long-term use; controversial)
Hepatotoxicity	Troglitazone (withdrawn); monitor LFTs with others
Anemia / hemodilution	Plasma volume expansion

3.5 ALPHA-GLUCOSIDASE INHIBITORS

Drugs

Acarbose, Miglitol, Voglibose

Mechanism

Competitively inhibit intestinal α-glucosidase enzymes (maltase, sucrase, dextrinase) at the brush border of the small intestine → delay carbohydrate digestion and absorption → blunt postprandial glucose rise

Clinical Effects

Reduce HbA1c by 0.5–0.8% (modest)
No hypoglycemia (when used alone)
May reduce postprandial cardiovascular risk (STOP-NIDDM trial)

Adverse Effects

GI: Flatulence, bloating, diarrhea, abdominal cramps (undigested carbohydrates fermented in colon) — dose-limiting
Liver toxicity (rare, high-dose acarbose)
Note: If hypoglycemia occurs while on acarbose + sulfonylurea → treat with glucose (dextrose), NOT sucrose (sucrose hydrolysis impaired)

3.6 DPP-4 INHIBITORS (Gliptins)

Drugs

Sitagliptin, Saxagliptin, Vildagliptin, Alogliptin, Linagliptin

Mechanism

Inhibit Dipeptidyl Peptidase-4 (DPP-4) enzyme → prevents degradation of GLP-1 and GIP (incretin hormones) → prolongs incretin action → ↑ glucose-dependent insulin secretion → ↓ glucagon secretion

Glucose-dependent → minimal hypoglycemia risk

Clinical Effects

Reduce HbA1c by 0.5–0.8%
Weight neutral
Linagliptin: no dose adjustment required in renal failure (biliary excretion)

Adverse Effects

Nasopharyngitis, upper respiratory infections
Pancreatitis (rare but black box warning)
Heart failure hospitalization risk — saxagliptin (SAVOR-TIMI trial); class concern
Arthralgia (rare, immune-mediated)

3.7 GLP-1 RECEPTOR AGONISTS

Drugs

Short-acting (daily): Exenatide (BID), Liraglutide (OD)
Long-acting (weekly): Semaglutide, Dulaglutide, Exenatide XR

Mechanism

GLP-1 receptor agonists (peptide analogs resistant to DPP-4 degradation) → bind GLP-1 receptors → ↑ glucose-dependent insulin secretion → ↓ glucagon → slow gastric emptying → ↑ satiety (central effect on hypothalamus)

Clinical Effects

Reduce HbA1c by 0.8–1.5%
Significant weight loss (1.5–6 kg) — best among oral/injectable antidiabetics
Cardiovascular benefit: Liraglutide (LEADER trial), Semaglutide (SUSTAIN-6) → ↓ MACE (CV death, MI, stroke)
Approved for weight management (semaglutide — Ozempic/Wegovy)

Adverse Effects

Nausea, vomiting, diarrhea (common, especially initially)
Pancreatitis (black box warning)
Thyroid C-cell tumors (rodent data → contraindicated with personal/family history of MTC or MEN2)
Injection site reactions

3.8 SGLT-2 INHIBITORS (Gliflozins)

Drugs

Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin

Mechanism

Inhibit Sodium-Glucose Cotransporter 2 (SGLT2) in the S1 segment of renal proximal tubule → block ~90% of filtered glucose reabsorption → glucosuria (~70–80 g glucose/day)

Also: natriuresis → ↓ blood pressure and preload

Clinical Effects

Reduce HbA1c by 0.5–1.0%
↓ Body weight 1–3 kg (caloric loss via urine)
↓ Blood pressure (5–7 mmHg)
Cardiovascular benefit: empagliflozin (EMPA-REG OUTCOME) → ↓ CV death, HF hospitalization in T2DM + CVD
Renoprotective: ↓ albuminuria, slow eGFR decline → approved in CKD (dapagliflozin)
Approved in Heart Failure (empagliflozin for HFrEF and HFpEF)

Adverse Effects

Effect	Details
Genital mycotic infections	Candidal vulvovaginitis / balanitis — most common
UTI	Glucosuria promotes bacterial growth
Diabetic ketoacidosis	Even with normal glucose (euglycemic DKA) — low insulin → ↑ glucagon → ↑ ketogenesis
Volume depletion / hypotension	Especially in elderly / loop diuretics
Fournier's gangrene	Rare — necrotizing fasciitis of perineum
Canagliflozin	↑ fracture risk, ↑ toe/foot amputations
Efficacy ↓ with eGFR < 45	Requires GFR to filter glucose

📊 COMPARISON SUMMARY TABLE

Drug Class	MOA	HbA1c ↓	Hypoglycemia	Weight	Key Advantage
Insulin	Direct replacement	Variable	Yes	↑↑	Works in all types
Metformin	↓ hepatic gluconeogenesis (AMPK)	1.0–1.5%	No	Neutral/↓	First-line; CV benefit
Sulfonylureas	Block K_ATP → ↑ insulin secretion	1.0–2.0%	Yes	↑	Effective; cheap
Meglitinides	Same as SU (diff site); rapid	0.5–1.5%	Low	↑	Postprandial control
TZDs	PPARγ activation → ↑ sensitivity	0.5–1.4%	No	↑↑	Insulin sensitizer
α-GI	↓ carbohydrate absorption	0.5–0.8%	No	Neutral	Postprandial
DPP-4i	↑ Incretins (GLP-1/GIP)	0.5–0.8%	No	Neutral	Well-tolerated
GLP-1 RA	GLP-1 receptor agonism	0.8–1.5%	No	↓↓	CV/weight benefit
SGLT-2i	↑ Renal glucose excretion	0.5–1.0%	No	↓	CV/renal protection

🎯 CLINICAL DECISION POINTS

Type 2 DM treatment algorithm (current guidelines):

First-line: Metformin (unless contraindicated)
+ ASCVD / HF / CKD: Add SGLT-2i or GLP-1 RA regardless of HbA1c
+ Need weight loss: GLP-1 RA preferred
+ Severe renal impairment (eGFR < 30): Use linagliptin (no renal dose adjustment)
Insulin: Type 1 DM (mandatory), T2DM with HbA1c > 10–11%, acute illness, surgery, DKA
Pregnancy: Insulin preferred; metformin/glyburide used in some centers

Remember:

Sulfonylureas + insulin = highest hypoglycemia risk
SGLT-2i = glucose-dependent → no hypoglycemia, but euglycemic DKA possible
Metformin + contrast: hold 48 h before/after procedure
Glyburide: avoid in elderly (prolonged active metabolites)
Pioglitazone: avoid in HF, bladder cancer risk
Liraglutide/semaglutide: contraindicated in personal/family history of medullary thyroid carcinoma

References: Katzung's Basic and Clinical Pharmacology 16e (Ch. 13, 41), Goldman-Cecil Medicine International Edition, Lippincott Illustrated Reviews Pharmacology, Ganong's Review of Medical Physiology 26e

This is a shared conversation. Sign in to Orris to start your own chat.